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Abstract
Background and methodology: Due to geographic overlap of malaria and visceral leishmaniasis (VL), co-infections may
exist but have been poorly investigated. To describe prevalence, features and risk factors for VL-malaria co-infections, a
case-control analysis was conducted on data collected at Amudat Hospital, Uganda (2000–2006) by Me ´decins sans
Frontie `res. Cases were identified as patients with laboratory-confirmed VL and malaria at hospital admission or during
hospitalization; controls were VL patients with negative malaria smears. A logistic regression analysis was performed to
study the association between patients’ characteristics and the occurrence of the co-infection.
Results: Of 2414 patients with confirmed VL, 450 (19%) were positively diagnosed with concomitant malaria. Most co-
infected patients were males, residing in Kenya (69%). While young age was identified by multivariate analysis as a risk
factor for concurrent VL and malaria, particularly the age groups 0–4 (odds ratio (OR): 2.44; 95% confidence interval (CI):
1.52–3.92) and 5–9 years (OR: 2.23, 95% CI: 1.45-3-45), mild (OR: 0.53; 95% CI: 0.32–0.88) and moderate (OR: 0.45; 95% CI:
0.27–0.77) anemia negatively correlated with the co-morbidity. VL patients harboring skin infections were nearly three times
less likely to have the co-infection (OR: 0.35; 95% CI: 0.17–0.72), as highlighted by the multivariate model. Anorexia was
slightly more frequent among co-infected patients (OR: 1.71; 95% CI: 0.96–3.03). The in-hospital case-fatality rate did not
significantly differ between cases and controls, being 2.7% and 3.1% respectively (OR: 0.87; 95% CI: 0.46–1.63).
Conclusions: Concurrent malaria represents a common condition among young VL patients living in the Pokot region of
Kenya and Uganda. Although these co-morbidities did not result in a poorer prognosis, possibly due to early detection of
malaria, a positive trend towards more severe symptoms was identified, indicating that routine screening of VL patients
living in malaria endemic-areas and close monitoring of co-infected patients should be implemented.
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Introduction
Due to extensive overlap in the geographical distribution of
many infectious diseases, multiple infections appear to be the rule
rather than the exception in many tropical and subtropical regions
[1]. Polyparasitism, in particular, may predominate in rural areas
of developing countries, where poor sanitation and economic
conditions allow the uninterrupted transmission of many parasites
[2–5]. Prevalences of multiparasite infections above 30% have
been shown to occur regularly throughout South-East Asia and
much of Central and West Africa, with communities harboring
multiple parasites in up to 80% of their population [6].
Importantly, the different combinations in which pathogens might
co-exist in a certain population and their distribution therein, do
not result from a random process, but they are rather part of a
selection governed by a variety of ecological and host factors,
which include the biological interactions of the parasites within the
host [3,7]. These interactions may affect the pathogenicity of the
infective agents, resulting in a spectrum of effects on the
polyparasitized host, ranging from exacerbation to amelioration
of disease severity [8]. Despite the recent upsurge in investigations
targeting multiple helminth species and Plasmodium-helminth co-
infections [9–12], the actual extent of polyparasitism and its
pathological consequences remain largely unassessed [8]. The
scarcity of information is particularly striking for infections that are
clinically not apparent or lack pathognomonic signs. As the tropics
www.plosntds.org 1 April 2012 | Volume 6 | Issue 4 | e1617and sub-tropics are burdened with infectious diseases sharing
similar clinical pictures, recognition of these diseases occurring in
the same patient might be difficult in poor resource settings.
Visceral leishmaniasis (VL) is a life-threatening syndrome
caused by protozoan parasites of the Leishmania donovani complex.
Most cases occur in East Africa, South-East Asia and Brazil, where
nearly 0.5 million people get infected each year [13], half of whom
are children [14]. Differential diagnosis of VL often includes
malaria amongst other febrile splenomegalies, due to its geo-
graphical and clinical overlap. Malaria, in fact, is widespread in
tropical and sub-tropical regions of the world, where it accounts
for more than 250 million cases annually, the vast majority of
which occurs among children under 5 years old [15]. Transmis-
sion can occur throughout the year or be seasonal, depending on
the region [16]. In the latter case, transmission seasons for VL and
malaria may not coincide, but the two diseases still overlap, due to
the longer incubation period of VL. The overlap in disease
distribution suggests the two diseases could co-occur in the same
host. Nonetheless, figures describing the extent of VL and malaria
co-infections are not readily available in literature.
To gather evidence on the occurrence of such co-morbidities, a
systematic review of the present literature was first conducted
(Figure S1). This review showed that cases of VL and malaria co-
infections have been reported across various African and Asian
countries, with the prevalence among VL patients ranging from
20.8% and 6.4% in Uganda [17,18] to 10.7% in Sudan [19] and
1.2% in Bangladesh [20] and a rate of 5.9% among Indian
patients with fever and splenomegaly [21]. With the exception of
the case-reports [22–25], whose evidence remains anecdotal, no
further details on these co-infections are described, preventing
identification of possible risk factors and specific features
associated with these co-morbidities. To address this issue, a
retrospective case-control analysis was performed on clinical data
of VL patients living in the Pokot territory of Kenya and Uganda
and admitted to Amudat Hospital, North-Eastern Uganda. The
area, a semi-arid lowland region mainly inhabited by pastoralists
of the Pokot tribe, is part of a large VL endemic focus, which
includes Pokot County in Uganda and extends eastwards to Pokot
North, West Pokot, East Pokot and Baringo Districts in Kenya
[26]. Here, VL is caused by Leishmania donovani and transmitted by
the sandfly Phlebotomus martini [26]. Malaria represents another
major health problem in the region, with incidence rates ranging
from 20% in Kenya to 30% in Uganda [15]. Hookworms and
other neglected tropical diseases such as lymphatic filariasis have
also been identified as endemic in the area [27]. Given such high
disease burdens, it is hardly surprising that polyparasitism may
represent a common condition.
The main goal of the present study was to describe the
prevalence of VL and malaria co-infections amongst VL patients
attending Amudat hospital and identify risk factors associated with
this condition. Recognition of the burden posed by these co-
morbidities among different patient groups may contribute to
improve the clinical management of VL in malaria-endemic areas.
Methods
Ethics statement
The analysis was conducted on anonymized data, collected as
part of routine patient care; no additional investigations were
performed. Therefore, no prior informed consent from the
patients was required. Ethical approval for the study was obtained
from the MSF Ethics Review Board (8
th April 2011).
Patients
Data of suspected VL patients admitted to Amudat Hospital, a
120-bed rural hospital located in Pokot County, Amudat District,
Uganda, were collected between January 2000 and December
2006 by Me ´decins sans Frontie `res (MSF-Swiss Section). MSF
support to Amudat Hospital medical activities included the
establishment of a VL control program, in which patients were
provided with free diagnosis and treatment. Clinically suspected
VL patients, defined as individuals with a history of prolonged
fever ($14 days) associated with either splenomegaly or wasting,
were included in MSF’s program and further examined for VL.
According to the diagnostic algorithm implemented [28], VL was
confirmed either serologically and/or parasitologically. Serological
tests included the direct agglutination test (DAT) and after 2004,
the rk39 antigen-based DiaMed IT-Leish dipstick, while parasi-
tological confirmation was obtained by microscopy examination of
spleen or, more rarely, lymph node aspirates. Microscopic
examination of thick and thin blood smears for malaria detection
was systematically performed at hospital admission or during
hospitalization. The diagnosis of other concomitant diseases was
based on clinical suspicion, possibly supported by laboratory-
confirmation. Testing for HIV was performed only occasionally,
due to the lack of voluntary counseling and testing facilities and the
shortage of antiretroviral treatment in the district. First-line
treatment for primary VL consisted of intramuscular meglumine
antimoniate (Glucantime
TM), temporarily replaced, due to drug
shortages, by intravenous ampothericin B deoxycholate or
intramuscular sodium stibogluconate (Pentostam
TM). Second-line
treatment based on amphotericin B deoxicholate was administered
in case of relapse or intolerance to antimonials. Chloroquine in
combination with sulfadoxine-pyrimethamine or alternatively
quinine was administered as first-line treatment for malaria.
Demographic and medical data of all VL suspected patients were
collected by MSF and the local medical staff and entered in a
Microsoft Excel data sheet. Besides outcomes of the performed
laboratory tests, the database gathered information on patients’
medical history, clinical presentation on admission, symptoms,
Author Summary
Visceral leishmaniasis (VL) and malaria are two major
parasitic diseases sharing a similar demographic and
geographical distribution. In areas where both diseases
are endemic, such as Sudan, Uganda, India and Bangla-
desh, co-infection cases have been reported, but features
and risk factors associated with these co-morbidities
remain poorly characterized. In the present study, routine-
ly collected data of VL patients admitted to Amudat
Hospital, Uganda, were used to investigate the magnitude
of VL-malaria co-infections and identify possible risk
factors. Nearly 20% of the patients included in this study
were found to be co-infected with VL and malaria,
indicating that this is a common condition among VL
patients living in malaria endemic areas. Young age (#9
years) was identified as an important risk factor for
contracting the VL-malaria co-infection, while being
anemic or carrying a skin infection appeared to negatively
correlate with the co-morbidity. Co-infected patients
presented with slightly more severe symptoms compared
to mono-infected patients, but had a similar prognosis,
possibly due to early diagnosis of malaria as a result of
systematic testing. In conclusion, these results emphasize
the importance of performing malaria screening amongst
VL patients living in malaria-endemic areas and suggest
that close monitoring of co-infected patients should be
implemented.
VL and Malaria Co-infections in Amudat Hospital
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relative outcome.
Data analysis
A retrospective case-control analysis was performed. Cases were
identified as patients with a laboratory-confirmed diagnosis of both
VL and malaria at hospital admission or during hospitalization;
controls were patients similarly diagnosed with VL, whose blood
smears tested negative for malaria. Descriptive analyses were
conducted to feature the overall study population and the co-
infected patients and to assess prevalence and mortality rates of the
co-infection. Statistical analysis was performed using SPSS 15.0
software (SPSS Inc., Chicago, IL, USA). Univariate analyses
exploring the association between the explanatory variables and
the outcome were performed, using the Pearson Chi-square test.
Specifically, risk factors, symptoms and the in-hospital death were
examined for their association with the co-infection. Associations
are shown as odds ratios (OR) with 95% confidence intervals (CI).
Denominators can vary for each variable because of incomplete
data in the database. Continuous variables were categorized into
predefined groups: age (0–4, 5–9, 10–19, 20–29, $30 years) based
on malaria risk, anemia on hemoglobin level (severe ,5.3 g/dl,
moderate 5.3–7.2 g/dl, mild 7.3–10.9 g/dl, none $11 g/dl) and
spleen size beneath the costal margin by tertiles (,11 cm, 11–
14 cm, .14 cm). Seasonality of the co-infection was examined by
categorizing hospital admissions during wet season (from March to
May, from October to November) and dry season (from December
to February, from June to September), which reflects the climate in
Uganda. Anthropometric indices –WHZ, weight-for-height Z-
score for children #5 years, BMIZ, body mass index Z-score for
children 6–19 years and BMI for patients .19 years– were used to
categorize nutritional status, according to the WHO standards
(severe malnutrition: WHZ and BMIZ,23SD, BMI,16 kg/m
2;
moderate-mild malnutrition: WHZ and BMIZ,22SD, BMI
16.0–18.4 kg/m
2; no malnutrition: WHZ and BMIZ.22SD,
BMI$18.5 kg/m
2) [29]. Self-reported symptoms experienced
prior to hospitalization were included in the analysis, with the
exception of the variable diarrhea, which combined episodes that
occurred prior to and during hospitalization. In order to identify
independent patient characteristics associated with the co-
infection, logistic regression models were constructed, using a
manual stepwise backward procedure to control for confounding
and describe statistical interactions. All variables with a P-
value,0.10 in the univariate analyses were entered stepwise in
the multivariate models. If an additional variable significantly
increased the model fit (as assessed by the 22 Log Likelihood test)
the variable was retained in the multivariate analysis (P,0.05).
Results
Prevalence, features and mortality rate of VL- malaria co-
infections
Between 2000 and 2006, a total of 4428 VL suspected patients
were admitted to Amudat Hospital, 57% of whom (n=2511) were
confirmed with VL. The diagnosis was confirmed by DAT in 1160
patients (46.2%), by DiaMed IT-Leish in 1115 patients (44.4%)
and by parasitological evidence in a spleen or lymph node aspirate
in 236 patients (9.4%). Of the 2511 VL-confirmed cases, 2461
(98%) were primary-VL infections, while the remaining 50 were
relapsing-cases. 547 (22%) of the VL-confirmed patients were co-
diagnosed with malaria at hospital admission or during hospital-
ization. Clinically-based diagnosis with negative or no microscopy
confirmation occurred for 97 patients, who were excluded from
the analysis. Only microscopy-confirmed cases of concomitant
malaria were retained for analysis in the co-infected group,
resulting in 19% of VL-confirmed patients (n=450 out of 2414)
co-infected with positively diagnosed malaria. Among the non-VL
cases, 1107 patients (25%) were clinically diagnosed with probable
hyper-reactive malarial splenomegaly, a severe syndrome fre-
quently observed among patients exposed to persistent malarial
antigenic stimulation. Most co-infected patients were males
residing in Kenya (69%), with a median age of 10 years (inter
quartile range 6–16) (table 2). With the highest percentage of cases
found among children aged between 0 and 4 years (26%, n=82/
316) and a progressive decrease with age (13%, n=32/251 in the
age group $30 years) (table 1), the odds of detecting malaria in
patients already diagnosed with VL appeared to be inversely
related to age.
Nearly all co- and mono-infected patients were diagnosed with a
degree of anemia (hemoglobin level ,11 g/dl) on hospital
admission, with a median hemoglobin level of 7.3 g/dl (inter
quartile range 6.7–9.7 for cases and 6.7–8.7 for controls) (table 2).
Splenomegaly, as detected here by palpation of the spleen below
the left costal margin, was also a common feature among co-
infected patients, but neither its frequency (75% for cases, 74% for
controls) nor its severity (median spleen size below the costal
margin 13.0 cm for cases and controls) were increased by the
malaria co-infection (table 2). More than half of the co-infected
patients were co-diagnosed with a third infectious disease,
reflecting the high prevalence of infections found in the study
area. Acute respiratory infections followed by otorhinolaryngolog-
ical and skin infections were the most common co-morbidities
among both cases and controls (table 3).
Of the 450 co-infected patients, 2.7% (n=12) died while
hospitalized. A similar in-hospital mortality rate was found in the
control group (3.1%, n=60) (OR: 0.87; 95% CI: 0.46–1.63) (data
not shown).
Risk factors for VL-malaria co-infections
Associations between demographic and clinical variables and
the co-infection, as described by the univariate analyses, are
summarized in Tables 2 and 3. Young age (#9 years) was
identified as a risk factor for the VL-malaria co-infection: in
particular, children in the age groups 0–4 (OR: 2.34; 95% CI:
1.53–3.75) and 5–9 years (OR: 2.02; 95% CI: 1.33–3.07) were
more than two times more likely to be co-infected compared to
adults $30 years. Transmission seasons for malaria and VL did
not coincide in the study area. However, no significant difference
was found in the seasonal distribution of cases’ and controls’
hospitalizations. VL-relapsing patients did not show different
Table 1. Prevalence of VL-malaria co-infections, stratified by
age, amongst VL patients from Amudat Hospital, Uganda,
2000–2006.
Total (n=2392)
*
Age group % n cases/ denominator
0–4 years 25.9 82/316
5–9 years 22.8 133/584
10–19 years 17.4 145/832
20–29 years 13.4 55/409
$30 years 12.7 32/251
*22 missing values for the variable age.
doi:10.1371/journal.pntd.0001617.t001
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with primary-VL infections, and were therefore maintained in the
relative groups (cases and controls). Malnourishment was relatively
more common in the control group, resulting in patients with
mild-moderate malnutrition being negatively associated with the
co-infection, compared to the well-nourished patients (OR: 0.73;
95% CI: 0.57–0.93). A significant negative association was found
between anemia and the co-infection: patients whose hemoglobin
level was ,11 g/dl, in fact, were less likely to be diagnosed with
the co-infection compared to the normochromic group. Among
concomitant diseases, patients diagnosed with a skin infection
(OR: 0.44, 95% CI: 0.22–0.88) were less likely to have the VL-
malaria co-infection. A trend towards a negative association was
also observed for patients suspected to harbor intestinal protozoa
and/or helminthes, possibly indicating a mutual protection among
the three diseases (OR: 0.25, 95% CI: 0.06–1.06). Finally,
Table 2. Characteristics associated with visceral leishmaniasis-malaria co-infections at Amudat Hospital, Uganda, 2000–2006 (part
I).
Variable
Malarial-VL co-
infection cases
Non-malarial VL
cases Crude Odds Ratio 95% Confidence Interval
n (%) n (%)
Gender 450 1964
Male 311 (69.1) 1350 (68.7) 1
Female 139 (30.9) 614 (31.3) 0.98 0.79–1.23
Age 447 1945
Median (inter-quartile range) 10 (6–16) 12 (7–21)
0–4 years 82 (18.3) 234 (12.0) 2.34 1.53–3.75*
5–9 years 133 (29.8) 451 (23.2) 2.02 1.33–3.07*
10–19 years 145 (32.4) 687 (35.3) 1.44 0.96–2.18*
20–29 years 55 (12.3) 354 (18.2) 1.06 0.67–1.70
$30 years 32 (7.2) 219 (11.3) 1
Country of origin 450 1962
Uganda 140 (31.1) 533 (27.2) 1
Kenya 310 (68.9) 1429 (72.8) 1.21 0.97–1.51
Season on admission 450 1964
Wet season 177 (39.3) 828 (42.2) 1
Dry season 273 (60.7) 1136 (57.8) 1.12 0.91–1.39
VL infection 450 1964
Primary infection 442 (98.2) 1922 (97.9) 1
Relapse 8 (1.8) 42 (2.1) 0.83 0.39–1.78
Previous VL treatment 450 1964
No 440 (97.8) 1928 (97.7) 1
Yes 10 (2.2) 46 (2.3) 0.95 0.45–1.89
Malnutrition 424 1882
No 168 (39.6) 638 (33.9) 1
Moderate-mild 142 (33.5) 744 (39.5) 0.73 0.57–0.93*
Severe 114 (26.9) 500 (26.6) 0.87 0.66–1.13
Anemia degree on admission 447 1938
Median hemoglobin g/dl (inter-quartile range) 7.3 (6.7–9.7) 7.3 (6.7–8.7)
None (Hemoglobin $11 g/dl) 26 (5.8) 68 (3.5) 1
Mild (Hemoglobin 7.3–10.9 g/dl) 276 (61.7) 1218 (62.8) 0.59 0.37–0.95*
Moderate (Hemoglobin 5.3–7.2 g/dl) 130 (29.1) 592 (30.5) 0.64 0.35–0.94*
Severe (Hemoglobin,5.3 g/dl) 15 (3.4) 60 (3.1) 0.91 0.32–1.35*
Spleen size on admission 443 1943
Median spleen size below the costal margin (inter-
quartile range)
13.0 (10.0–15.0) 13.0 (10.0–16.0)
,11 cm 111 (25.1) 513 (26.4) 1
11–14 cm 191 (43.1) 752 (38.7) 1.17 0.91–1.52
.14 cm 141 (31.8) 678 (34.9) 0.96 0.73–1.26
*P-value,0.10 based on Person Chi-square tests.
doi:10.1371/journal.pntd.0001617.t002
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CI: 0.92–3.11), and vomiting (OR: 2.87, 95% CI: 0.79–10.39)
were identified as positively associated symptoms of the VL-
malaria co-infection, while a negative association was found for
diarrhea (OR: 0.59, 95% CI: 0.38–0.92).
All 9 variables associated with the co-infection in the univariate
analyses were included in the multivariate logistic regression
models. Two separate models were created, due to the high
number of missing data in reporting the symptoms: model A,
based on 2306 patients, which includes all variables except the
symptoms and model B, based on 929 patients, which combines
symptoms and all other variables. Model A (table 4) shows that,
after adjusting for the other variables in the model, mild-moderate
malnutrition lost its statistical significance (P-value 0.18). However,
the variable was kept in the final model as it was found to be a
confounder for age. After adjusting for the other variables included
in the model, age #9 years remained significantly associated with
the co-infection. When compared to adults $30 years, the risk of
being diagnosed with the co-morbidity was highest among
children aged 0–4 years (OR: 2.44; 95% CI: 1.52–3.92) and
progressively decreased with age (OR: 2.23; 95% CI: 1.45–3.45
for age group 5–9 years; OR: 1.48; 95% CI: 0.97–2.26 for age
group 10–19 years). Moderate (OR: 0.45; 95% CI: 0.27–0.77) and
mild anemia (OR: 0.53; 95% CI: 0.32–0.88) negatively correlated
with the co-infection. Finally, the model highlighted a negative
association between being co-infected with VL and malaria and
carrying a skin infection (OR: 0.35; 95% CI: 0.17–0.72) and, to a
lesser extent, intestinal parasites (OR: 0.28; 95% CI 0.07–1.19).
Table 3. Characteristics associated with visceral leishmaniasis-malaria co-infections at Amudat Hospital, Uganda, 2000–2006 (part
II).
Variable
Malarial-VL co-
infection cases
Non-malarial VL
cases Crude Odds Ratio 95% Confidence Interval
n (%) n (%)
Concomitant diagnoses 450 1964
Acute respiratory infections 165 (36.7) 653 (33.2) 1.09 0.94–1.44
Ear, nose and throat infections
# 46 (10.2) 234 (11.9) 1.01 0.73–1.26
Skin infections
{ 9 (2.0) 87 (4.4) 0.44 0.22–0.88*
Bacterial infections
{ 7 (1.6) 15 (0.8) 1.91 0.83–5.07
Chicken pox 3 (0.7) 19 (1.0) 2.04 0.20–2.33
Tuberculosis 2 (0.4) 7 (0.4) 0.75 0.26–6.03
Brucellosis 3 (0.5) 15 (0.8) 0.71 0.21–2.46
Typhoid fever 0 9 (0.5) 1.00 0.99–1.00
Intestinal parasites
1 2 (0.4) 34 (1.7) 0.25 0.06–1.06*
Hepatopathy 1 (0.2) 8 (0.4) 0.55 0.07–4.37
Other infections 4 (0.9) 37 (1.9) 0.47 0.17–1.32
Symptoms on admission 81 908
Cough 34 (42.0) 380 (41.9) 1.01 0.63–1.59
Weight loss 29 (35.8) 267 (29.4) 1.34 0.83–2.16
Anorexia 19 (23.5) 129 (14.2) 1.85 1.07–3.20*
Bleeding 15 (18.5) 192 (21.1) 0.85 0.47–1.52
Headache 13 (16.0) 164 (18.1) 0.87 0.47–1.61
Malaise 14 (17.3) 100 (11.0) 1.69 0.92–3.11*
Diarrhea 23 (5.1) 165 (8.4) 0.59 0.38–0.92*
Vomiting 3 (3.7) 12 (1.3) 2.87 0.79–10.39*
Fatigue 2 (2.5) 25 (2.8) 0.89 0.21–3.85
Abdominal distension 1 (1.2) 11 (1.2) 1.02 0.13–8.00
Edema 1 (1.2) 26 (2.9) 0.42 0.06–3.17
Abdominal pain 1 (1.2) 14 (1.5) 0.80 0.10–6.15
Jaundice 1 (1.2) 10 (1.1) 1.12 0.14–8.88
Joint pain 0 12 (1.3) 1.00 0.99–1.00
Sweating 1 (1.2) 8 (0.9) 1.41 0.17–11.39
Palpitations 0 3 (0.3) 1.00 0.99–1.00
Skin rash 0 3 (0.3) 1.00 0.99–1.00
*P-value,0.10 based on Person Chi-square tests.
#Ear, nose and throat infections include: otitis, pharyngitis, sinusitis, tonsillitis, parotitis, gingivitis and noma.
{Skin infections include bacterial and fungal infections.
{Bacterial infections include: infections of the urinary tract, sepsis and other infections.
1Intestinal parasite infections include protozoan and helminthic infections.
doi:10.1371/journal.pntd.0001617.t003
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times less likely to be diagnosed with the co-infection.
In model B (table 5), logistic regression was performed on the
sub cohort of patients for whom symptoms, besides the other
variables, were reported. As anemia was found to be a confounder
in the association between age and the co-infection, the variable
was kept in the model. Besides concomitant diagnoses, diarrhea,
vomiting and malaise lost their significance and were consequently
excluded from the model. The association between anorexia and
the co-infection also lost its statistical significance in the
multivariate analysis, but the variable was kept in the model as
it increased the model fit. A positive association with this symptom
can be seen (OR: 1.71; 95% CI: 0.96–3.03), indicating that co-
infected patients more frequently reported anorexia among their
symptoms.
Discussion
Nineteen percent of the VL-confirmed patients admitted to
Amudat Hospital between 2000 and 2006 were co-diagnosed with
malaria. Young age (#9 years) was identified as a risk factor for
concomitant VL and malaria, while being anemic or having a skin
infection appeared to negatively correlate with the co-infection.
Anorexia was slightly more frequent among co-infected patients
compared to the mono-infected ones. The in-hospital case-fatality
rate did not significantly differ between cases and controls,
indicating that VL-malaria co-infections did not result in a poorer
prognosis.
Affecting nearly one out of five VL patients, VL and malaria co-
infections appeared to be a common condition among VL patients
living in the Pokot Region of Kenya and Uganda. Though in
agreement with the findings of Mueller et al. who investigated the
in-hospital mortality of VL within the same study population [17],
the co-infection rate described in the present population (19%) is
one of the highest so far reported, as identified by our systematic
literature review. The main reason behind this variation may be
found in the malaria prevalence characterizing the study areas
(31% and 18% in Uganda and Kenya, respectively, 28% in
Sudan, 0.31% in India and 2.0% in Bangladesh in the
corresponding study years [15,30]). This case, however, does not
apply to the study of Kolaczinski et al. [18], in which only 6.4% of
the Amudat Hospital VL patients recruited between June and
September 2006 were reported to be co-infected with malaria.
Although different malaria diagnostics were used to define the two
study populations (microscopy in the present study and the
Plasmodium falciparum-specific Paracheck test in Kolaczinski’s study),
the role played by the use of such diagnostic tools is likely to be
marginal, considering the high performance of the Paracheck test
in Uganda [31], where P. falciparum causes most of malaria
infections [15]. Most likely, the higher co-infection prevalence
observed here resulted from recruiting a larger number of study
subjects. When examining only patients hospitalized in the same
four-month period of 2006, indeed, the co-infection rate remains
significantly higher (19%), even in comparison with the malaria
prevalence estimated by Kolaczinski et al. (16%), emphasizing the
importance of recruiting large numbers of participants.
The co-infected population described by the present study
mainly consisted of male Kenyans (69%), with a median age of 10
years. Despite the similar demographic pattern found among the
controls, young age appeared to be positively associated with the
co-infection; children #9 years, in fact, were found to be more
than two times more likely to be co-infected with malaria,
compared to adults $30 years, reflecting the well-known age
patterns of malaria [32].
Table 4. Model A: multivariate analysis of risk factors for VL-
malaria co-infections among 2306 Amudat Hospital patients.
Variable
Odds
Ratio
95% Confidence
Interval P-value
Age
0–4 years 2.44 1.52–3.92 ,0.010
5–9 years 2.23 1.45-3-45 ,0.010
10–19 years 1.48 0.97–2.26 0.067
20–29 years 1.09 0.67–1.76 0.730
$30 years 1 ,0.001
Malnutrition
No 1 0.295
Moderate-mild 0.84 0.64–1.08 0.176
Severe 1.01 0.77–1.33 0.955
Anemia on admission
None (Hb$11 g/dl) 1 0.035
Mild (Hb 7.3–10.9 g/dl) 0.53 0.32–0.88 0.014
Moderate (Hb 5.3–7.2 g/dl) 0.45 0.27–0.77 0.004
Severe (Hb,5.3 g/dl) 0.49 0.22–1.08 0.075
Concomitant diagnoses
Skin infections 0.35 0.17–0.72 0.005
Intestinal parasites 0.28 0.07–1.19 0.085
doi:10.1371/journal.pntd.0001617.t004
Table 5. Model B: multivariate analysis of symptoms
associated to VL-malaria co-infections among 929 Amudat
Hospital patients.
Variable
Odds
Ratio
95% Confidence
Interval P-value
Age
0–4 years 3.19 1.09–9.32 0.034
5–9 years 2.99 1.10–8.13 0.032
10–19 years 0.86 0.31–2.45 0.783
20–29 years 0.85 0.26–2.77 0.785
$30 years 1 ,0.001
Malnutrition
No 1 0.522
Moderate-mild 1.10 0.61–1.98 0.748
Severe 1.41 0.77–2.60 0.265
Anemia on admission
None (Hb$11 g/dl) 1 0.199
Mild (Hb 7.3–10.9 g/dl) 0.31 0.06–1.54 0.154
Moderate (Hb 5.3–7.2 g/dl) 0.24 0.05–1.21 0.083
Severe (Hb,5.3 g/dl) 0.19 0.03–1.38 0.101
Symptoms
Malaise 2.14 1.12–4.07 0.021
Anorexia 1.71 0.96–3.03 0.070
doi:10.1371/journal.pntd.0001617.t005
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correlated with the co-occurrence of malaria in VL patients.
Given the bi-directional nature of such association, it is not
possible to determine a priori whether such correlation might reflect
the reduced susceptibility of VL anemic patients to the malarial
infection or simply result from the interaction of the two diseases
upon each another. Splenic-associated hemolysis and reduced
hematopoiesis, as a result of abnormal iron retention by
macrophages, have been implicated in the multifactorial origin
of VL-induced anemia, where both hemoglobin and plasma iron
levels are affected [33]. Iron-deficiency, in particular, was
associated with delay in the in vitro intraerythrocytic growth of
Plasmodium parasites [34] and protection from mild clinical malaria
in vivo [35]. Although in our study population, anemia was
diagnosed on the basis of the hemoglobin levels only, iron
deficiency might be equally common, due to poor nutritional
status and ongoing diseases, providing temporary resistance to the
malaria disease. A less severe course of VL as a result of
concomitant malaria might represent a possible scenario, corrob-
orated by the findings that severe splenomegaly and fatal outcome
were slightly less common among co-infected patients. The milder
anemia observed among co-infected patients compared to mono-
infected patients could then be the result of a malaria-mitigating
effect on VL. Such hypothesis, however, appears to be in contrast
with previous observations obtained from animal models, in which
the course of Leishmania infections appeared to be unaffected or
exacerbated by the concomitant presence of Plasmodium parasites
[36–39]. In addition, the more frequent reporting of anorexia by
co-infected patients seems to point towards an exacerbation of
disease severity rather than alleviation. The hypothesis whereby
co-infected patients may be diagnosed at earlier stage than VL
mono-infected patients, due to more severe symptoms, is unlikely,
as no difference was found in the ongoing sickness duration of
cases and controls prior to hospitalization. The severe dehydration
observed in some patients may have led to misleading (elevated)
hemoglobin levels on hospital admission. However, the significant
increase in hemoglobin level observed after treatment (+2.14 g/dl)
suggests that severe dehydration may have played only a marginal
role. Finally, it should be noted that the groups comprising the
non-anemic patients consisted of relatively few patients for both
cases and controls, which may limit the validity of the associations
described. In fact, when patients with no anemia and mild anemia
(the most numerous group) are grouped together, the association
between moderate anemia and the VL-malaria co-infection looses
its significance (data not shown).
Unlike what may be observed in other co-morbidities [40,41],
co-infections with VL and malaria did not result in an exacerbated
spleen enlargement compared to VL mono-infections. This may
be related to splenic disorders promoted by VL, which might be
hampering for the malaria-induced hyperplasia. Remarkably,
while massive splenomegaly is a common feature of VL, it is more
rarely associated to malarial infections, which instead induce only
moderate spleen enlargement. Therefore, exacerbation of spleno-
megaly as promoted by concomitant malaria might have occurred
but be undetectable due to the larger effect produced by VL on the
spleen size. Finally, a possible malaria-induced attenuation of VL
severity should not be excluded.
More than half of the patients among both cases and controls
were co-diagnosed with one or more infections beyond VL and
malaria. If this figure reflects the high infectious disease burdens
found in the study area, we cannot exclude the development of co-
morbidities to be related to the VL infection. Importantly, if VL
might have favored the superimposing of other infections, malaria
neither exacerbated the susceptibility of co-infected patients nor
influenced the concomitant disease-pattern, with the exception of
skin infections and, to a lesser extent, intestinal parasites. VL
patients diagnosed with bacterial and fungal skin infections, in fact,
appeared to be more than two times less likely to be co-diagnosed
with malaria, although no evident explanation could be found.
Similarly, a negative, but not significant association between co-
infected patients and VL patients suspected to harbor intestinal
parasites was identified, suggesting that the parasites involved
(intestinal protozoa and/or helminthes, Leishmania and Plasmodium
spp) may be able to cross-regulate their host susceptibility. It
should be noted, however, that diagnosis of intestinal parasitic
infections for some patients might have been based on clinical
suspicion only, with no laboratory-confirmation, and that testing
for these parasites might have not been performed systematically,
as suggested by the very low prevalence of positive patients (1.5%).
A dedicated study recruiting larger patient cohorts diagnosed with
intestinal parasitic infections and performing systematic testing of
all study subject would be required to confirm this finding.
Anorexia was reported slightly more frequently in the co-
infected group than in the mono-infected group, indicating that a
more severe clinical picture may be associated with the
overlapping of the two diseases. This symptom was frequently
associated with the malarial infection; however, the significance of
such finding remains questionable, given the relatively small
number of patients which it is based on. Importantly, if VL-
malaria co-infections were associated with a worse symptomatol-
ogy, they did not result in a poorer prognosis among patients
properly diagnosed and treated. The overall fatality-rate, in fact,
was similar in the co-infected group as in the mono-infected one,
suggesting that here, malaria and its treatment neither altered the
severity of VL and its responsiveness to chemotherapy nor resulted
in an increased toxicity of the anti-leishmanial drugs. A similar
conclusion might be extended to the co-infected patients
diagnosed with relapses rather than primary infections, as no
death occurred among these patients. Whether the prognosis of
co-infected patients in whom malaria remained undetected and/or
untreated may be different, is hard to predict, but a higher
mortality risk may be expected, as observed for late diagnosed
malaria.
The findings highlighted by the present study may be
generalized with caution to the VL-symptomatic population
residing in the Uganda-Kenya VL foci. Evidence in support of
this statement includes the large catchment area of Amudat
Hospital, its specialization in VL and the local awareness of the
disease. Until November 2006, when MSF transferred its medical
activities to Kacheliba Health Centre in Kenya, Amudat Hospital
was the only reliable facility available in the region for the
diagnosis and treatment of VL. Furthermore, a recent study
conducted in the same area indicated that VL is a well-known
disease among members of the Pokot communities, who not only
recognize its main clinical signs and poor prognosis, but are also
aware that drug treatment is available and effective [18]. This
resulted in many individuals with symptoms of VL presenting
voluntarily to the MSF’s VL-ward, where VL diagnosis and
treatment were provided free of charge by MSF.
The main limitations of this study relate to data quality and lack
of mono-infected malaria patients and healthy controls. It was not
possible to assess the malaria prevalence in the study area, which
prevented us from calculating the VL associated risk of being-co-
diagnosed with malaria. Comparison of study variables was only
possible for VL co-and mono-infected patients, possibly reducing
the significance of some of the associations found. The lack of
quality control on malaria microscopy might have led to poor
performance, possibly affecting the accuracy of the study results.
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subject to interpretation, been based on the Lovibond method.
Spleen size measurement might have suffered from poor
standardization, with different physicians using slightly different
techniques.
In conclusion, this study highlights for the first time that
concurrent VL and malaria infection represents a common co-
morbidity among young patients living in highly malaria-endemic
areas, such as the Pokot territory of Kenya and Uganda. Based on
these findings, we recommend that malaria screening be
implemented for all VL patients residing in malaria-endemic
areas in order to promptly initiate antimalarial drug treatment.
Future studies are needed to address the complicated question on
whether the concurrency of such infections might influence the
course of one or both diseases in humans. This may be of
importance for the design of successful disease control programs.
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